What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

To evaluate the efficacy of TAS-102 combined with celecoxib in colorectal cancer patients with ctDNA-defined minimal residual disease.

View Full Paper

Ask AI

Bookmark

Authors

Phase 2 trial shows improved ctDNA clearance in colorectal cancer with TAS-102 and celecoxib, indicating potential for better outcomes.

To evaluate the efficacy of TAS-102 combined with celecoxib in colorectal cancer patients with ctDNA-defined minimal residual disease.
Single-center, non-randomized phase 2 trial
Patients with stage II-IV colorectal cancer and detectable ctDNA
Combination treatment of TAS-102 and celecoxib administered for 6 months
Primary end point: 6-month ctDNA clearance rate
Safety and tolerability monitored throughout the trial.
33% ctDNA clearance rate at 6 months from TAS-102 monotherapy
47% ctDNA clearance at 3 months
60% of patients had radiographic recurrence after a median follow-up of 14.8 months
Celecoxib shows synergetic potential with cytotoxic therapies.

Bent et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark